These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35589388)

  • 1. Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis.
    Park H; Desai R; Liu X; Smith SM; Hincapie-Castillo J; Henry L; Goodin A; Gopal S; Pepine CJ; Mohandas R
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):851-860. PubMed ID: 35589388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.
    Wang C; Kane R; Levenson M; Kelman J; Wernecke M; Lee JY; Kozlowski S; Dekmezian C; Zhang Z; Thompson A; Smith K; Wu YT; Wei Y; Chillarige Y; Ryan Q; Worrall C; MaCurdy TE; Graham DJ
    JAMA Intern Med; 2016 Dec; 176(12):1818-1825. PubMed ID: 27775769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States.
    Wright DG; Wright EC; Narva AS; Noguchi CT; Eggers PW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1822-30. PubMed ID: 26358266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Safety of Long-Acting vs. Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis.
    Desai R; Unigwe I; Riaz M; Smith SM; Shukla AM; Mohandas R; Jeon N; Park H
    Clin Pharmacol Ther; 2024 Jul; 116(1):217-224. PubMed ID: 38629679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.
    McCullough PA; Barnhart HX; Inrig JK; Reddan D; Sapp S; Patel UD; Singh AK; Szczech LA; Califf RM
    Am J Nephrol; 2013; 37(6):549-58. PubMed ID: 23735819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.
    Chertow GM; Liu J; Monda KL; Gilbertson DT; Brookhart MA; Beaubrun AC; Winkelmayer WC; Pollock A; Herzog CA; Ashfaq A; Sturmer T; Rothman KJ; Bradbury BD; Collins AJ
    J Am Soc Nephrol; 2016 Oct; 27(10):3129-3138. PubMed ID: 26917691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis.
    Rheault MN; Molony JT; Nevins T; Herzog CA; Chavers BM
    Kidney Int; 2017 Jan; 91(1):177-182. PubMed ID: 27865440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
    N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
    Locatelli F; Hannedouche T; Fishbane S; Morgan Z; Oguey D; White WB
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1701-1710. PubMed ID: 31420350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginesatide in patients with anemia undergoing hemodialysis.
    Fishbane S; Schiller B; Locatelli F; Covic AC; Provenzano R; Wiecek A; Levin NW; Kaplan M; Macdougall IC; Francisco C; Mayo MR; Polu KR; Duliege AM; Besarab A;
    N Engl J Med; 2013 Jan; 368(4):307-19. PubMed ID: 23343061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Epoetin Alfa Titration Practices, Implemented After Changes to Product Labeling, on Hemoglobin Levels, Transfusion Use, and Hospitalization Rates.
    Molony JT; Monda KL; Li S; Beaubrun AC; Gilbertson DT; Bradbury BD; Collins AJ
    Am J Kidney Dis; 2016 Aug; 68(2):266-276. PubMed ID: 26980607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of anemia with epoetin alfa in chronic kidney disease.
    Singh AK; Szczech L; Tang KL; Barnhart H; Sapp S; Wolfson M; Reddan D;
    N Engl J Med; 2006 Nov; 355(20):2085-98. PubMed ID: 17108343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM - HD Study.
    Kuo KL; Hung SC; Tseng WC; Tsai MT; Liu JS; Lin MH; Hsu CC; Tarng DC;
    J Am Heart Assoc; 2018 Aug; 7(15):e009206. PubMed ID: 30371224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS).
    Brunelli SM; Monda KL; Burkart JM; Gitlin M; Neumann PJ; Park GS; Symonian-Silver M; Yue S; Bradbury BD; Rubin RJ
    Am J Kidney Dis; 2013 Jun; 61(6):947-56. PubMed ID: 23332991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.
    Strippoli GF;
    Trials; 2010 Jun; 11():70. PubMed ID: 20534124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
    Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
    Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.